WO1993009863A1 - System for processing separate containers of biological fluid - Google Patents

System for processing separate containers of biological fluid Download PDF

Info

Publication number
WO1993009863A1
WO1993009863A1 PCT/US1992/010034 US9210034W WO9309863A1 WO 1993009863 A1 WO1993009863 A1 WO 1993009863A1 US 9210034 W US9210034 W US 9210034W WO 9309863 A1 WO9309863 A1 WO 9309863A1
Authority
WO
WIPO (PCT)
Prior art keywords
biological fluid
gas
assembly
pooling
receiving container
Prior art date
Application number
PCT/US1992/010034
Other languages
French (fr)
Inventor
Vlado I. Matkovich
Thomas J. Bormann
Thomas C. Gsell
Frank R. Pascale
Original Assignee
Pall Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pall Corporation filed Critical Pall Corporation
Priority to GB9409479A priority Critical patent/GB2276097B/en
Priority to JP50954293A priority patent/JP3173009B2/en
Priority to EP93900579A priority patent/EP0675752B1/en
Priority to DE69224219T priority patent/DE69224219T2/en
Publication of WO1993009863A1 publication Critical patent/WO1993009863A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/02Blood transfusion apparatus
    • A61M1/0209Multiple bag systems for separating or storing blood components
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/02Blood transfusion apparatus
    • A61M1/0209Multiple bag systems for separating or storing blood components
    • A61M1/0218Multiple bag systems for separating or storing blood components with filters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/02Blood transfusion apparatus
    • A61M1/0209Multiple bag systems for separating or storing blood components
    • A61M1/0231Multiple bag systems for separating or storing blood components with gas separating means, e.g. air outlet through microporous membrane or gas bag
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3621Extra-corporeal blood circuits
    • A61M1/3643Priming, rinsing before or after use
    • A61M1/3644Mode of operation
    • A61M1/3646Expelling the residual body fluid after use, e.g. back to the body
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3621Extra-corporeal blood circuits
    • A61M1/3643Priming, rinsing before or after use
    • A61M1/3644Mode of operation
    • A61M1/3652Mode of operation using gas, e.g. air
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00Special media to be introduced, removed or treated
    • A61M2202/04Liquids
    • A61M2202/0413Blood
    • A61M2202/0439White blood cells; Leucocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/75General characteristics of the apparatus with filters
    • A61M2205/7527General characteristics of the apparatus with filters liquophilic, hydrophilic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/75General characteristics of the apparatus with filters
    • A61M2205/7536General characteristics of the apparatus with filters allowing gas passage, but preventing liquid passage, e.g. liquophobic, hydrophobic, water-repellent membranes

Definitions

  • This invention relates to a system, apparatus, and method for processing separate containers of biological fluid.
  • PC platelet concentrate
  • platelets are notorious for being "sticky", an expression reflecting the tendency of platelets suspended in blood plasma to adhere to any non-physiological surface (e.g., the surfaces of the components of a system for processing biological fluid) to which they are exposed. Under many circumstances, they also adhere strongly to each other.
  • Biological fluid includes any treated or untreated fluid associated with living organisms, particularly blood, including whole blood, warm or cold blood, and stored or fresh blood; treated blood, such as blood diluted with a physiological solution, including but not limited to saline, nutrient, and/or anticoagulant solutions; blood components, such as platelet concentrate (PC) , platelet-rich plasma (PRP) , platelet-free plasma, platelet-poor plasma (PPP) , plasma, buffy coat (BC) or packed red cells (PRC) ; analogous blood products derived from blood or a blood component or derived from bone marrow; red cells separated from plasma and resuspended in physiological fluid; and platelets separated from plasma and resuspended in physiological fluid.
  • the biological fluid may include'leukocytes, or may be treated to remove leukocytes.
  • biological fluid refers to the components described above, and to similar blood products obtained by other means and with similar properties.
  • (B) Unit of PC or platelets As used herein, a unit of PC or of platelets in physiological fluid or plasma, is the quantity derived from one unit of whole blood. Typically, the volume of a unit varies. Multiple units of platelets may be pooled or combined, typically by combining four or more units.
  • Porous medium A porous medium is one through which one or more biological fluids pass.
  • the porous medium for use with biological fluids may be formed from any natural or synthetic fiber or from a porous or permeable membrane (or from other materials of similar surface area and pore size) compatible with biological fluid.
  • the surface of the fibers or membrane may be unmodified or may be modified to achieve a desired property.
  • the medium may be subjected to gas plasma treatment, preferably in order to reduce platelet adhesion.
  • the fibers or membrane are preferably treated in order to reduce or eliminate platelet adherence to the medium. Any treatment which reduces or eliminates platelet adhesion is included within the scope of the present invention.
  • the fibers may be surface modified as disclosed in U.S. Patent 4,880,548, in order to increase the critical wetting surface tension (CWST) of the fibers and to be less adherent of platelets.
  • CWST critical wetting surface tension
  • a preferred range of CWST for a porous medium according to the invention is above about 70 dynes/cm, more preferably above about 90 dynes/cm.
  • the porous medium may be pre-formed, single or multi-layered, and/or may be treated to modify the fiber surfaces either before or after forming the fibrous lay-up.
  • the porous medium may be configured in any suitable fashion, such as a flat sheet, a corrugated sheet, a web, hollow fibers, or a membrane.
  • Processes and systems according to the invention include a manifold assembly for combining multiple units of a biological fluid in independent containers into a single container. Processes and systems according to the invention may also include a leukocyte depletion assembly.
  • processes and systems according to the invention may include a gas inlet and/or a gas outlet that maximizes the recovery of a biological fluid that may be entrapped or retained during processing; the processes and systems may also include a drip chamber that collects gas and/or controls the rate of flow of a biological fluid through the system.
  • the processes and systems of the present invention provide for increased yield of a biological fluid, since valuable fluid that would normally be retained in various elements of a biological fluid processing system may now be recovered.
  • the present invention also provides for reduced processing time and operator labor.
  • the Figure is an embodiment of a biological fluid processing system comprising a manifold assembly according to the invention.
  • units of biological fluid particularly PC, which are in separate source containers, are passed through a biological fluid processing system which maximizes recovery of the biological fluid into a single receiving container.
  • the processing system may also include a leukocyte depletion assembly that is interposed between the source containers and the receiving container.
  • Manifold assembly 100 may include containers 20, each suitable for holding at least one unit of a biological fluid such as PC, in fluid communication with a pooling assembly 21.
  • the pooling assembly 21 includes a network or plurality of conduits 40 that converge into a single conduit 60 at outlet or junction 50. Some of the conduits 40 function as inlets from the source containers 20.
  • pooling assembly 21 may include a housing having at least two inlets and an outlet. The outlet or junction 50 of the pooling assembly 21 is in fluid communication with a receiving or transfer container 22.
  • fluid communication with the receiving container 22 is preferably established by a conduit 60.
  • a conduit 60 Interposed in the conduit 60 between the outlet or junction 50 and the container 22 may be at least one device or assembly.
  • the manifold assembly 100 may include a gas inlet 30, a drip chamber 31, a leukocyte depletion assembly 32, and a gas outlet 33.
  • the source and receiving containers which are used in the biological fluid processing assembly may be constructed of any material compatible with biological fluids.
  • these containers are already known in the art.
  • blood collection and satellite bags are typically made from plasticized PVC, e.g. PVC plasticized with dioctylphthalate, diethylhexylphthalate, or trioctyltrimellitate.
  • the bags may also be formed from a pol olefin, polyurethane, polyester, or a polycarbonate.
  • the pooling assembly of the instant invention provides fluid communication between at least two source containers and a receiving container, more preferably between three or more source containers and a receiving container, preferably by channeling multiple flow paths into a single flow path.
  • the pooling assembly 21 preferably comprises a plurality of conduits 40 and an outlet or junction 50.
  • the conduits can be configured in a number of ways, the pooling assembly preferably comprises a network or tiered arrangement of conduits 40, preferably including one or more junctions, such as one or more Y-connectors.
  • the conduits provide fluid communication between the source of the biological fluid, such as separate unit containers 20, and a multiple unit container, such as transfer or receiving container 22.
  • a clamp, seal, valve, transfer leg closure, or the like, may be located within or on at least one of the conduits.
  • the pooling assembly 21 may include at least one device having multiple inlets and a single outlet in fluid communication with junction 50.
  • the pooling assembly used in the instant invention may be constructed of any material compatible with a biological fluid.
  • the pooling assembly may be composed of a non- flexible material, for example, acrylonitrile butadiene styrene (ABS) , polycarbonate, or stainless steel.
  • ABS acrylonitrile butadiene styrene
  • it may be composed of a flexible material, such as polyvinyl chloride (PVC) , or plasticized PVC, e.g., PVC plasticized with dioctylphthalate, diethylhexylphthalate, or trioctyltrimellitate.
  • PVC polyvinyl chloride
  • plasticized PVC e.g., PVC plasticized with dioctylphthalate, diethylhexylphthalate, or trioctyltrimellitate.
  • the biological fluid processing system may include a drip chamber 31.
  • drip chamber 31 may be used to prevent gas from reaching a leukocyte depletion assembly 32 and/or the receiving container 22 downstream of the drip chamber, and for maximizing recovery of the biological fluid.
  • the drip chambers which may be used in the biological fluid processing assembly may be constructed of any material compatible with biological fluid and gas.
  • the drip chamber may include at least one porous element, preferably a liquophobic porous membrane, that allows gas into a biological fluid processing system and/or allows gas to be separated from a biological fluid being processed, e.g., allows gas out of a biological fluid processing system, but resists the passage of biological fluid.
  • the porous element would then function as a gas inlet and/or a gas outlet as later discussed.
  • the porous element may be positioned in a conduit, or, more preferably, it may be included in a housing of the drip chamber. Further, the surface of the element may be oriented in a variety of ways with respect to the flow of the biological fluid. For example, two porous elements may be placed at opposite ends or sides of the drip chamber, or a single element may be offset within the drip chamber.
  • the leukocyte depletion assembly 32 comprises at least one porous medium which removes leukocytes from the biological fluid.
  • Exemplary leukocyte depletion media for use with a biological fluid such as PC are disclosed in U.S. Patent 4,880,548.
  • the leukocyte depletion assembly 32 may be positioned in the manifold assembly in a variety of ways. For example, it may be located downstream of the outlet of the pooling assembly 50 and the drip chamber 31.
  • a plurality of leukocyte depletion assemblies may be used in connection with the pooling assembly of the instant invention. For example, a plurality of leukocyte depletion assemblies may placed in a plurality of pooling assembly inlets, i.e., in direct communication with the individual source containers of biological fluid.
  • a plurality of leukocyte depletion assemblies may be placed more downstream in the pooling assembly, i.e., at similar or different tiers of the pooling assembly.
  • a leukocyte depletion assembly 32 is interposed between the source containers 20 and the receiving container 22, for example, in conduit 60.
  • a gas inlet and/or a gas outlet may be used to maximize the recovery of biological fluid in receiving or transfer container 22.
  • the gas inlet 30 and the gas outlet 33 may be, respectively, upstream and downstream of the leukocyte depletion assembly 32. More preferably, as exemplified in the Figure, the gas inlet 30 is downstream of the outlet of the pooling assembly 50 and upstream of the drip chamber 31, which is upstream of the leukocyte depletion assembly 32, while the gas outlet 33 is downstream, interposed between the leukocyte depletion assembly 32 and the receiving or transfer container 22.
  • a gas inlet and/or a gas outlet may be positioned in a drip chamber, a conduit, or the receiving and/or source containers.
  • the gas inlet is a porous element which allows gas into a biological fluid processing system.
  • the gas inlet may provide for increasing the recovery of a valuable biological fluid (e.g., PC) that may otherwise be retained in various components of the manifold assembly during processing and would otherwise be lost.
  • a valuable biological fluid e.g., PC
  • the gas outlet is a porous element which allows gas to be separated from a biological fluid being processed.
  • the gas outlet allows gas that may be present in a biological fluid processing system out of the system.
  • the gas outlet may provide for minimizing the volume of gases that remain in, or in contact with, a biological fluid during processing.
  • the gas outlet may also allow gas into the biological fluid processing system.
  • the gas inlet and gas outlet should be chosen so that the sterility of the system is not compromised.
  • the gas inlet and gas outlet each comprise at least one porous element designed to allow gas to pass therethrough.
  • a variety of materials may be used, provided the requisite properties of the porous element are achieved. These properties include the necessary strength to handle the differential pressures encountered in use and the ability to provide the desired filtration capability while providing the desired permeability without the application of excessive pressure.
  • the porous elements of the gas inlet and the gas outlet should also preferably have a pore rating of about 0.2 micrometer or less to preclude bacteria entering the system.
  • the gas inlet and gas outlet include at least one liquophobic porous element. Because the liquophobic porous element is not wettable, or poorly wettable, by the biological fluid being processed in the system, gas in the system that contacts the liquophobic element will pass through it, while the biological fluid will not.
  • the gas outlet may also include at least one liquophilic porous element, that allows gas to exit, but not enter, the system.
  • the gas outlet includes both a liquophobic membrane and a liquophilic membrane.
  • the gas inlet and/or the gas outlet may be included in a housing, which may include a cap or closure. Exemplary gas inlets and/or gas outlets and processes for using them are as disclosed in International Publication Nos. WO 91/17809 and WO 92/07656, and U. S. Patent No. 5,126,054.
  • the placement of the gas inlet and/or the gas outlet may be optimized to achieve a desired result.
  • the gas inlet 30 may be located as far upstream of the manifold outlet or junction 50 as is practical in order to sufficiently maximize the recovery of biological fluid from the manifold assembly 100.
  • gas inlets may be located in each of the source containers 20 of the biological fluid to be pooled.
  • the gas inlet 30 may be placed in a conduit 40 or downstream of the outlet or junction 50 of the pooling assembly 21.
  • the gas outlet 33 may be located in conduit 60 downstream of the outlet or junction 50 and as close to receiving or transfer container 22 as is possible in order to maximize the volume of gas that is removed from the manifold assembly 100.
  • the gas outlet may be located in the receiving or transfer container 22 itself.
  • the gas inlet or the gas outlet may be located in the drip chamber 31.
  • a gas inlet and/or a gas outlet may be interposed between the source containers 20 and the receiving container 22, for example, in conduit 60.
  • the pooling assembly may also include a plurality of gas inlets and/or gas outlets in any of the containers, or in any of the conduits communicating with the leukocyte depletion assemblies.
  • PC in a plurality of containers 20 passes through the conduits of the pooling assembly 21 and through outlet or junction 50 to receiving or transfer container 22.
  • the PC preferably contacts at least one device, assembly, or porous element, e.g., a gas inlet 30, a drip chamber 31, or a gas outlet 33, for preventing gas from reaching a leukocyte depletion assembly or the receiving container, and for maximizing the recovery of the PC, which is interposed between the source containers 20 and the receiving or transfer container 22.
  • the PC may also pass through at least one leukocyte depletion assembly 32 which is interposed between the source containers 20 and the receiving or transfer container 22.
  • air or gas may be introduced into the source containers 20 through the gas inlet assembly 30 or the gas outlet assembly 33, preferably by using a syringe (not shown) .
  • air or gas refers to any gaseous fluid, such as sterilized air, oxygen, carbon dioxide, and the like; it is intended that the invention not be limited to the type of gas used.
  • the introduced fluid is preferably ambient air or a sterile gas, some non- gaseous fluids may also be suitable.
  • fluid that is lighter than the biological fluid and is non-reactive with it is included within the scope of the present invention.
  • Introducing gas into the source containers 20 may be accomplished by opening a flow path from the gas inlet 30 or the gas outlet 33 to the appropriate source container 20, while closing the flow path to the receiving or transfer container 22.
  • the clamps on the conduits leading to the receiving or transfer container 22 and all but one container 20 may be closed, so that when gas is introduced into the system, gas in the conduit will enter the open container.
  • the process includes introducing gas sequentially into the source containers 20. The flow path to each source container may be closed after gas has been introduced into that container. The flow path from the gas inlet 30 or the gas outlet 33 is then closed.
  • the flow path to the first source container 20 is then opened, and as the PC passes from the first source container 20, and flows through the pooling assembly 21 toward receiving or transfer container 22, it displaces the gas that was ahead of the column of flowing PC; this gas is exhausted or removed from the system.
  • the gas may be vented from the system through a porous element in the drip chamber or in the conduit, or preferably, through an open gas outlet 33.
  • the gas outlet may be inactivated to prevent gas from entering the system.
  • the gas outlet may be inactivated by manually closing the outlet, e.g., by capping or clamping.
  • the gas outlet includes a liquophobic element, and more preferably, both a liquophobic element and a liquophilic element, which inactivates the outlet automatically, upon wetting by the PC.
  • clamps adjacent to the other source containers are opened, preferably, sequentially, so that PC from the other containers 20 may pass through the pooling assembly 21 toward the receiving or transfer container 22.
  • the clamp adjacent to the receiving or transfer container 22 is opened so that the PC can flow into the container 22.
  • the clamp adjacent to the receiving or transfer container 22 is opened before the clamps adjacent to the other source containers are opened.
  • Initiating the flow of PC from the other source containers also displaces gas ahead of the other units of PC.
  • this gas may be collected in drip chamber 31 interposed between the outlet or junction 50 and the receiving or transfer container 22. Passing the PC through a drip chamber 31 may include collecting gas and/or controlling the rate of flow of the PC.
  • the drip chamber 31 is typically inverted until the PC fills the drip chamber, at which point the drip chamber is returned to its normal orientation.
  • the PC may also be passed through a leukocyte depletion assembly 32 interposed between the outlet or junction 50 of the manifold assembly 21 and the receiving or transfer container 22.
  • the leukocyte depletion assembly 32 is located between the gas inlet 30 and the gas outlet 33.
  • the gas ahead of the PC may be exhausted through the gas outlet 33 as described previously. Pooled PC is then recovered in the receiving or transfer container 22 and, in accordance with the invention, the introduction of air or gas into the receiving container is eliminated or minimized, so the PC is recovered without collecting air.
  • gas may be introduced behind the PC retained in the system.
  • the gas that was initially introduced into the source containers 20 through either the gas inlet 30 or the gas outlet 33 will follow the PC as it flows through the conduits. This increases the recovery of the PC, since the gas following the PC "chases" the fluid from the conduits.
  • gas may be introduced behind the retained PC by opening gas inlet 30. Additional PC may then be recovered in the receiving or transfer container 22.
  • receiving or transfer container 22 may be sealed and separated from the system, without the introduction of air into the container.
  • receiving or transfer container 22 is heat sealed, although other methods of sealing are also suitable.
  • the gas outlet may be used as a gas inlet, and, conversely, the gas inlet may be used as a gas outlet, at different stages of processing of the PC.
  • gas may be introduced and exhausted using a gas inlet and a gas outlet as described above, and the PC is recovered in a receiving or transfer container. Gas may then be introduced through the gas outlet, so that the PC remaining in the containers and/or held up in the leukocyte depletion assembly or assemblies may be collected.
  • gas may also be introduced through the gas inlet for a similar effect. Further embodiments are encompassed by the present invention.
  • the manifold assembly 100 may comprise all of the components shown in the Figure, except for the leukocyte depletion assembly 32.
  • Another embodiment of the invention may comprise all of the components shown in the Figure except for the gas inlet 30, the leukocyte depletion assembly 32, and the gas outlet 33.
  • the drip chamber 31 preferably includes a porous element for venting gas.
  • another embodiment of the invention may include only a single porous element interposed between the outlet of the pooling assembly 50 and the receiving or transfer container 22, which allows gas to flow therethrough. In each of these embodiments gas ahead of the flow of the PC. and gas pockets moving along the conduit with the flow of PC may be prevented from entering the receiving or transfer container.
  • an apparatus for processing biological fluid comprises a conduit having first and second ends and interposed between the first end and the second end, at least one of a gas inlet, a drip chamber, a leukocyte depletion assembly, and a gas outlet.
  • an apparatus may comprise a conduit having first and second ends and interposed between the first end and the second end, a gas inlet, a drip chamber, a leukocyte depletion assembly, and a gas outlet.
  • At least one of the gas inlet, the drip chamber and the gas outlet may comprise at least one porous element for maximizing recovery of a biological fluid.
  • the porous element may comprise at least one liquophobic element, and may also include at least one liquophilic element.
  • the invention also encompasses a method for processing biological fluid comprising passing a biological fluid through a conduit having first and second ends and interposed between the first and second ends, at least one of a gas inlet, a drip chamber, a leukocyte depletion assembly, and a gas outlet.
  • a method may comprise passing a biological fluid through a conduit having first and second ends and interposed between the first and second ends, a gas inlet, a drip chamber, a leukocyte depletion assembly, and a gas outlet.
  • the pooling assembly used to perform this example utilized six units of PC in individual 60 ml single-unit containers, and a 1500 ml storage container, set up in a manner that generally corresponds to that described for the Figure.
  • the manifold assembly is arranged generally vertically, with the pooling assembly and the conduit to the receiving container having a total length of about 24 inches. Clamps on the conduits adjacent to the six single-unit containers of PC were closed, as was the clamp on the conduit between the transfer container and the gas outlet.
  • the leukocyte depletion assembly was produced in accordance with U.S. Patent 4,880,548.
  • a 60 cc syringe was used to introduce air through the gas inlet and into the source containers.
  • the gas outlet was capped.
  • the plunger of the syringe was drawn back to the "60 cc" mark, the gas inlet was uncapped, and then the syringe was connected to the gas inlet.
  • the clamp to the first single-unit container which contained a unit of PC, was opened, and the plunger of the syringe was pushed forward about 5-10 cc, thus introducing air into the first single-unit container.
  • the clamp to that first container was then closed.
  • the same procedure was followed with respect to the remaining five single-unit containers.
  • the syringe was then removed, the gas inlet was recapped, and the gas outlet was uncapped.
  • the clamp to the first container was then opened to allow the PC to flow from the first container, and the drip chamber was inverted and squeezed to fill the chamber.
  • the drip chamber was then returned to its normal orientation, and the PC flowed through the drip chamber and leukocyte depletion assembly, toward the transfer container. Air was exhausted through the opened gas outlet, until the PC contacted the liquophobic membrane in the gas outlet.

Abstract

Processes and systems for combining multiple units of a biological fluid in independent containers (20) into a single receiving container (22) via a pooling assembly (21) are disclosed. The pooling assembly (21) includes a plurality of conduits (40) that converge into a single conduit (60) at outlet (50). Interposed in the conduit (60) between the outlet (50) and the receiving container (22) may include a gas inlet (30), a drip chamber (31), a leukocyte depletion assembly (32), and a gas outlet (33).

Description

SYSTEM FOR PROCESSING SEPARATE CONTAINERS OF BIOLOGICAL FLUID
Technical Field
This invention relates to a system, apparatus, and method for processing separate containers of biological fluid.
Background of the Invention
The development of plastic blood collection bags facilitated the separation of donated whole blood into its various components, thereby making platelet concentrate (PC) available as a transfusion product. Typically, random-donor PC is produced from a unit of whole blood by differential sedimentation. The need for specific blood components is growing rapidly as the therapeutic administration of these components increases. The net result is twofold: biological fluids are increasingly important, and the need to maximize yield has increased. Thus, any amount that is retained in the processing system, or is recovered but is not viable and physiologically active, represents a potentially significant loss. While the failure to maximize yield is a serious concern with respect to all blood components, it is particularly applicable to the production of PC, since typical procedures for processing platelet containing solutions such as PC fail to efficiently maximize platelet recovery. The recovery of platelets may be adversely affected during the preparation of platelet concentrate in several ways. For example, platelets are notorious for being "sticky", an expression reflecting the tendency of platelets suspended in blood plasma to adhere to any non-physiological surface (e.g., the surfaces of the components of a system for processing biological fluid) to which they are exposed. Under many circumstances, they also adhere strongly to each other.
As detailed in U.S. Patent No. 4,880,548, which discloses methods and devices for leukocyte depleting blood components, including PC, there will be substantial contact between platelets and the internal surfaces of the leukocyte depletion device. It is therefore desirable that the leukocyte depletion device should minimize platelet loss due to that contact and should not adversely affect platelet viability or physiological activity.
This problem is magnified when multiple units of platelet containing suspensions are pooled or processed. When multiple units of PC from random donors are pooled for transfusion into a patient, some of the fluid is trapped or retained in the individual collection and processing assemblies, collectively representing a significant loss if the highly valuable fluid can not be recovered. In view of this, there is a growing need for a system and method for economically and efficiently processing a biological fluid, such as a platelet containing suspension, that will not only pool large amounts (e.g. multiple units) of the fluid, but will also leukocyte deplete the fluid and maximize the recovery of platelets.
Disclosure of Invention
The following definitions are used in reference to the invention: (A) Biological Fluid: Biological fluid includes any treated or untreated fluid associated with living organisms, particularly blood, including whole blood, warm or cold blood, and stored or fresh blood; treated blood, such as blood diluted with a physiological solution, including but not limited to saline, nutrient, and/or anticoagulant solutions; blood components, such as platelet concentrate (PC) , platelet-rich plasma (PRP) , platelet-free plasma, platelet-poor plasma (PPP) , plasma, buffy coat (BC) or packed red cells (PRC) ; analogous blood products derived from blood or a blood component or derived from bone marrow; red cells separated from plasma and resuspended in physiological fluid; and platelets separated from plasma and resuspended in physiological fluid. The biological fluid may include'leukocytes, or may be treated to remove leukocytes. As used herein, biological fluid refers to the components described above, and to similar blood products obtained by other means and with similar properties.
(B) Unit of PC or platelets: As used herein, a unit of PC or of platelets in physiological fluid or plasma, is the quantity derived from one unit of whole blood. Typically, the volume of a unit varies. Multiple units of platelets may be pooled or combined, typically by combining four or more units.
(C) Porous medium: A porous medium is one through which one or more biological fluids pass.
The porous medium for use with biological fluids may be formed from any natural or synthetic fiber or from a porous or permeable membrane (or from other materials of similar surface area and pore size) compatible with biological fluid. The surface of the fibers or membrane may be unmodified or may be modified to achieve a desired property. For example, the medium may be subjected to gas plasma treatment, preferably in order to reduce platelet adhesion.
Although the porous medium may remain untreated, the fibers or membrane are preferably treated in order to reduce or eliminate platelet adherence to the medium. Any treatment which reduces or eliminates platelet adhesion is included within the scope of the present invention. For example, the fibers may be surface modified as disclosed in U.S. Patent 4,880,548, in order to increase the critical wetting surface tension (CWST) of the fibers and to be less adherent of platelets. Defined in terms of CWST, a preferred range of CWST for a porous medium according to the invention is above about 70 dynes/cm, more preferably above about 90 dynes/cm. The porous medium may be pre-formed, single or multi-layered, and/or may be treated to modify the fiber surfaces either before or after forming the fibrous lay-up. The porous medium may be configured in any suitable fashion, such as a flat sheet, a corrugated sheet, a web, hollow fibers, or a membrane.
Processes and systems according to the invention include a manifold assembly for combining multiple units of a biological fluid in independent containers into a single container. Processes and systems according to the invention may also include a leukocyte depletion assembly.
Additionally, processes and systems according to the invention may include a gas inlet and/or a gas outlet that maximizes the recovery of a biological fluid that may be entrapped or retained during processing; the processes and systems may also include a drip chamber that collects gas and/or controls the rate of flow of a biological fluid through the system.
The processes and systems of the present invention provide for increased yield of a biological fluid, since valuable fluid that would normally be retained in various elements of a biological fluid processing system may now be recovered. The present invention also provides for reduced processing time and operator labor.
Brief Description of the Drawings
The Figure is an embodiment of a biological fluid processing system comprising a manifold assembly according to the invention.
Modes for Carrying Out the Invention
In accordance with the present invention, units of biological fluid, particularly PC, which are in separate source containers, are passed through a biological fluid processing system which maximizes recovery of the biological fluid into a single receiving container. The processing system may also include a leukocyte depletion assembly that is interposed between the source containers and the receiving container.
An exemplary biological fluid processing system which may be a sterile system, and more preferably, a closed, sterile system, is shown in the Figure. Manifold assembly 100 may include containers 20, each suitable for holding at least one unit of a biological fluid such as PC, in fluid communication with a pooling assembly 21. In the illustrated embodiment, the pooling assembly 21 includes a network or plurality of conduits 40 that converge into a single conduit 60 at outlet or junction 50. Some of the conduits 40 function as inlets from the source containers 20. Alternatively, pooling assembly 21 may include a housing having at least two inlets and an outlet. The outlet or junction 50 of the pooling assembly 21 is in fluid communication with a receiving or transfer container 22. In the illustrated embodiment, fluid communication with the receiving container 22 is preferably established by a conduit 60. Interposed in the conduit 60 between the outlet or junction 50 and the container 22 may be at least one device or assembly. For example, as shown in the illustrated embodiment, the manifold assembly 100 may include a gas inlet 30, a drip chamber 31, a leukocyte depletion assembly 32, and a gas outlet 33.
Each of the components of the invention will now be described in more detail below.
The source and receiving containers which are used in the biological fluid processing assembly may be constructed of any material compatible with biological fluids. A wide variety of these containers are already known in the art. For example, blood collection and satellite bags are typically made from plasticized PVC, e.g. PVC plasticized with dioctylphthalate, diethylhexylphthalate, or trioctyltrimellitate. The bags may also be formed from a pol olefin, polyurethane, polyester, or a polycarbonate.
The pooling assembly of the instant invention provides fluid communication between at least two source containers and a receiving container, more preferably between three or more source containers and a receiving container, preferably by channeling multiple flow paths into a single flow path. As illustrated in the Figure, the pooling assembly 21 preferably comprises a plurality of conduits 40 and an outlet or junction 50. Although the conduits can be configured in a number of ways, the pooling assembly preferably comprises a network or tiered arrangement of conduits 40, preferably including one or more junctions, such as one or more Y-connectors. As used herein, the conduits provide fluid communication between the source of the biological fluid, such as separate unit containers 20, and a multiple unit container, such as transfer or receiving container 22. A clamp, seal, valve, transfer leg closure, or the like, may be located within or on at least one of the conduits.
Alternatively, the pooling assembly 21 may include at least one device having multiple inlets and a single outlet in fluid communication with junction 50.
The pooling assembly used in the instant invention may be constructed of any material compatible with a biological fluid. For example, the pooling assembly may be composed of a non- flexible material, for example, acrylonitrile butadiene styrene (ABS) , polycarbonate, or stainless steel. Alternatively, it may be composed of a flexible material, such as polyvinyl chloride (PVC) , or plasticized PVC, e.g., PVC plasticized with dioctylphthalate, diethylhexylphthalate, or trioctyltrimellitate.
In accordance with another embodiment of the invention, the biological fluid processing system may include a drip chamber 31. As noted in more detail below, drip chamber 31 may be used to prevent gas from reaching a leukocyte depletion assembly 32 and/or the receiving container 22 downstream of the drip chamber, and for maximizing recovery of the biological fluid. The drip chambers which may be used in the biological fluid processing assembly may be constructed of any material compatible with biological fluid and gas. Furthermore, the drip chamber may include at least one porous element, preferably a liquophobic porous membrane, that allows gas into a biological fluid processing system and/or allows gas to be separated from a biological fluid being processed, e.g., allows gas out of a biological fluid processing system, but resists the passage of biological fluid. The porous element would then function as a gas inlet and/or a gas outlet as later discussed. The porous element may be positioned in a conduit, or, more preferably, it may be included in a housing of the drip chamber. Further, the surface of the element may be oriented in a variety of ways with respect to the flow of the biological fluid. For example, two porous elements may be placed at opposite ends or sides of the drip chamber, or a single element may be offset within the drip chamber.
The leukocyte depletion assembly 32 comprises at least one porous medium which removes leukocytes from the biological fluid. Exemplary leukocyte depletion media for use with a biological fluid such as PC are disclosed in U.S. Patent 4,880,548. The leukocyte depletion assembly 32 may be positioned in the manifold assembly in a variety of ways. For example, it may be located downstream of the outlet of the pooling assembly 50 and the drip chamber 31. A plurality of leukocyte depletion assemblies may be used in connection with the pooling assembly of the instant invention. For example, a plurality of leukocyte depletion assemblies may placed in a plurality of pooling assembly inlets, i.e., in direct communication with the individual source containers of biological fluid. Alternatively, a plurality of leukocyte depletion assemblies may be placed more downstream in the pooling assembly, i.e., at similar or different tiers of the pooling assembly. In a preferred embodiment, a leukocyte depletion assembly 32 is interposed between the source containers 20 and the receiving container 22, for example, in conduit 60.
In another embodiment, a gas inlet and/or a gas outlet may be used to maximize the recovery of biological fluid in receiving or transfer container 22. Preferably, the gas inlet 30 and the gas outlet 33 may be, respectively, upstream and downstream of the leukocyte depletion assembly 32. More preferably, as exemplified in the Figure, the gas inlet 30 is downstream of the outlet of the pooling assembly 50 and upstream of the drip chamber 31, which is upstream of the leukocyte depletion assembly 32, while the gas outlet 33 is downstream, interposed between the leukocyte depletion assembly 32 and the receiving or transfer container 22. Alternatively, a gas inlet and/or a gas outlet may be positioned in a drip chamber, a conduit, or the receiving and/or source containers. The gas inlet is a porous element which allows gas into a biological fluid processing system. Thus, the gas inlet may provide for increasing the recovery of a valuable biological fluid (e.g., PC) that may otherwise be retained in various components of the manifold assembly during processing and would otherwise be lost.
The gas outlet is a porous element which allows gas to be separated from a biological fluid being processed. For example, the gas outlet allows gas that may be present in a biological fluid processing system out of the system. Thus, the gas outlet may provide for minimizing the volume of gases that remain in, or in contact with, a biological fluid during processing. The gas outlet may also allow gas into the biological fluid processing system.
The gas inlet and gas outlet should be chosen so that the sterility of the system is not compromised.
The gas inlet and gas outlet each comprise at least one porous element designed to allow gas to pass therethrough. A variety of materials may be used, provided the requisite properties of the porous element are achieved. These properties include the necessary strength to handle the differential pressures encountered in use and the ability to provide the desired filtration capability while providing the desired permeability without the application of excessive pressure. In a closed system, the porous elements of the gas inlet and the gas outlet should also preferably have a pore rating of about 0.2 micrometer or less to preclude bacteria entering the system.
Preferably, the gas inlet and gas outlet include at least one liquophobic porous element. Because the liquophobic porous element is not wettable, or poorly wettable, by the biological fluid being processed in the system, gas in the system that contacts the liquophobic element will pass through it, while the biological fluid will not. The gas outlet may also include at least one liquophilic porous element, that allows gas to exit, but not enter, the system. In a preferred embodiment of the invention, the gas outlet includes both a liquophobic membrane and a liquophilic membrane. Additionally, the gas inlet and/or the gas outlet may be included in a housing, which may include a cap or closure. Exemplary gas inlets and/or gas outlets and processes for using them are as disclosed in International Publication Nos. WO 91/17809 and WO 92/07656, and U. S. Patent No. 5,126,054.
As noted above, the placement of the gas inlet and/or the gas outlet may be optimized to achieve a desired result. For example, the gas inlet 30 may be located as far upstream of the manifold outlet or junction 50 as is practical in order to sufficiently maximize the recovery of biological fluid from the manifold assembly 100. Thus, gas inlets may be located in each of the source containers 20 of the biological fluid to be pooled. Alternatively, the gas inlet 30 may be placed in a conduit 40 or downstream of the outlet or junction 50 of the pooling assembly 21.
Also, it may be desirable to locate the gas outlet 33 in conduit 60 downstream of the outlet or junction 50 and as close to receiving or transfer container 22 as is possible in order to maximize the volume of gas that is removed from the manifold assembly 100. Alternatively, the gas outlet may be located in the receiving or transfer container 22 itself. The gas inlet or the gas outlet may be located in the drip chamber 31. In a preferred embodiment of the invention, a gas inlet and/or a gas outlet may be interposed between the source containers 20 and the receiving container 22, for example, in conduit 60.
Included within the scope of the invention is the use of more than one gas inlet and/or gas outlet. For example, when the pooling assembly includes a plurality of leukocyte depletion assemblies, the pooling assembly may also include a plurality of gas inlets and/or gas outlets in any of the containers, or in any of the conduits communicating with the leukocyte depletion assemblies.
A method according to the invention may be described with reference to the Figure, where the components are shown in a preferably vertical arrangement, with the source containers 20 at the highest point. Biological fluid, as used hereinafter, PC, in a plurality of containers 20 passes through the conduits of the pooling assembly 21 and through outlet or junction 50 to receiving or transfer container 22. As the PC flows, it preferably contacts at least one device, assembly, or porous element, e.g., a gas inlet 30, a drip chamber 31, or a gas outlet 33, for preventing gas from reaching a leukocyte depletion assembly or the receiving container, and for maximizing the recovery of the PC, which is interposed between the source containers 20 and the receiving or transfer container 22. In accordance with the present invention, the PC may also pass through at least one leukocyte depletion assembly 32 which is interposed between the source containers 20 and the receiving or transfer container 22.
In order to maximize recovery of PC prior to processing, air or gas may be introduced into the source containers 20 through the gas inlet assembly 30 or the gas outlet assembly 33, preferably by using a syringe (not shown) . As used herein, air or gas refers to any gaseous fluid, such as sterilized air, oxygen, carbon dioxide, and the like; it is intended that the invention not be limited to the type of gas used. While the introduced fluid is preferably ambient air or a sterile gas, some non- gaseous fluids may also be suitable. For example, fluid that is lighter than the biological fluid and is non-reactive with it is included within the scope of the present invention.
Introducing gas into the source containers 20 may be accomplished by opening a flow path from the gas inlet 30 or the gas outlet 33 to the appropriate source container 20, while closing the flow path to the receiving or transfer container 22. For example, the clamps on the conduits leading to the receiving or transfer container 22 and all but one container 20 may be closed, so that when gas is introduced into the system, gas in the conduit will enter the open container. In a preferred embodiment, the process includes introducing gas sequentially into the source containers 20. The flow path to each source container may be closed after gas has been introduced into that container. The flow path from the gas inlet 30 or the gas outlet 33 is then closed. The flow path to the first source container 20 is then opened, and as the PC passes from the first source container 20, and flows through the pooling assembly 21 toward receiving or transfer container 22, it displaces the gas that was ahead of the column of flowing PC; this gas is exhausted or removed from the system. The gas may be vented from the system through a porous element in the drip chamber or in the conduit, or preferably, through an open gas outlet 33. Once the gas has been exhausted from the system, the gas outlet may be inactivated to prevent gas from entering the system. For example, the gas outlet may be inactivated by manually closing the outlet, e.g., by capping or clamping. Preferably, the gas outlet includes a liquophobic element, and more preferably, both a liquophobic element and a liquophilic element, which inactivates the outlet automatically, upon wetting by the PC. Once the gas ahead of the PC column has been exhausted and the flow of PC has stopped, clamps adjacent to the other source containers are opened, preferably, sequentially, so that PC from the other containers 20 may pass through the pooling assembly 21 toward the receiving or transfer container 22. The clamp adjacent to the receiving or transfer container 22 is opened so that the PC can flow into the container 22. Preferably, the clamp adjacent to the receiving or transfer container 22 is opened before the clamps adjacent to the other source containers are opened.
Initiating the flow of PC from the other source containers also displaces gas ahead of the other units of PC. Preferably, this gas may be collected in drip chamber 31 interposed between the outlet or junction 50 and the receiving or transfer container 22. Passing the PC through a drip chamber 31 may include collecting gas and/or controlling the rate of flow of the PC. The drip chamber 31 is typically inverted until the PC fills the drip chamber, at which point the drip chamber is returned to its normal orientation.
In accordance with the invention, the PC may also be passed through a leukocyte depletion assembly 32 interposed between the outlet or junction 50 of the manifold assembly 21 and the receiving or transfer container 22. Preferably, the leukocyte depletion assembly 32 is located between the gas inlet 30 and the gas outlet 33. An exemplary process for passing the PC through a leukocyte depletion assembly is disclosed in U.S. Patent No. 4,880,548.
As the PC passes through the drip chamber 31 and the optional leukocyte depletion assembly 32, the gas ahead of the PC may be exhausted through the gas outlet 33 as described previously. Pooled PC is then recovered in the receiving or transfer container 22 and, in accordance with the invention, the introduction of air or gas into the receiving container is eliminated or minimized, so the PC is recovered without collecting air.
In order to maximize recovery of PC, gas may be introduced behind the PC retained in the system. The gas that was initially introduced into the source containers 20 through either the gas inlet 30 or the gas outlet 33 will follow the PC as it flows through the conduits. This increases the recovery of the PC, since the gas following the PC "chases" the fluid from the conduits. Furthermore, after the PC has passed through the pooling assembly into the receiving or transfer container 22 and the source containers 20 have collapsed, gas may be introduced behind the retained PC by opening gas inlet 30. Additional PC may then be recovered in the receiving or transfer container 22.
Once recovery of PC has been completed, receiving or transfer container 22 may be sealed and separated from the system, without the introduction of air into the container. Preferably, receiving or transfer container 22 is heat sealed, although other methods of sealing are also suitable.
Other variations are encompassed by the present invention. Thus, the gas outlet may be used as a gas inlet, and, conversely, the gas inlet may be used as a gas outlet, at different stages of processing of the PC. For example, gas may be introduced and exhausted using a gas inlet and a gas outlet as described above, and the PC is recovered in a receiving or transfer container. Gas may then be introduced through the gas outlet, so that the PC remaining in the containers and/or held up in the leukocyte depletion assembly or assemblies may be collected. Of course, gas may also be introduced through the gas inlet for a similar effect. Further embodiments are encompassed by the present invention. For example, in one embodiment, the manifold assembly 100 may comprise all of the components shown in the Figure, except for the leukocyte depletion assembly 32. Another embodiment of the invention may comprise all of the components shown in the Figure except for the gas inlet 30, the leukocyte depletion assembly 32, and the gas outlet 33. In this variation, the drip chamber 31 preferably includes a porous element for venting gas. Additionally, another embodiment of the invention may include only a single porous element interposed between the outlet of the pooling assembly 50 and the receiving or transfer container 22, which allows gas to flow therethrough. In each of these embodiments gas ahead of the flow of the PC. and gas pockets moving along the conduit with the flow of PC may be prevented from entering the receiving or transfer container. Further, gas may be introduced behind the flow of PC to maximize recovery of the PC. In another variation encompassed by the invention, an apparatus for processing biological fluid comprises a conduit having first and second ends and interposed between the first end and the second end, at least one of a gas inlet, a drip chamber, a leukocyte depletion assembly, and a gas outlet. For example, an apparatus may comprise a conduit having first and second ends and interposed between the first end and the second end, a gas inlet, a drip chamber, a leukocyte depletion assembly, and a gas outlet. At least one of the gas inlet, the drip chamber and the gas outlet may comprise at least one porous element for maximizing recovery of a biological fluid. The porous element may comprise at least one liquophobic element, and may also include at least one liquophilic element.
The invention also encompasses a method for processing biological fluid comprising passing a biological fluid through a conduit having first and second ends and interposed between the first and second ends, at least one of a gas inlet, a drip chamber, a leukocyte depletion assembly, and a gas outlet. For example, a method may comprise passing a biological fluid through a conduit having first and second ends and interposed between the first and second ends, a gas inlet, a drip chamber, a leukocyte depletion assembly, and a gas outlet.
Example
The pooling assembly used to perform this example utilized six units of PC in individual 60 ml single-unit containers, and a 1500 ml storage container, set up in a manner that generally corresponds to that described for the Figure. The manifold assembly is arranged generally vertically, with the pooling assembly and the conduit to the receiving container having a total length of about 24 inches. Clamps on the conduits adjacent to the six single-unit containers of PC were closed, as was the clamp on the conduit between the transfer container and the gas outlet. The leukocyte depletion assembly was produced in accordance with U.S. Patent 4,880,548.
A 60 cc syringe was used to introduce air through the gas inlet and into the source containers. The gas outlet was capped. The plunger of the syringe was drawn back to the "60 cc" mark, the gas inlet was uncapped, and then the syringe was connected to the gas inlet. The clamp to the first single-unit container, which contained a unit of PC, was opened, and the plunger of the syringe was pushed forward about 5-10 cc, thus introducing air into the first single-unit container. The clamp to that first container was then closed. The same procedure was followed with respect to the remaining five single-unit containers.
The syringe was then removed, the gas inlet was recapped, and the gas outlet was uncapped. The clamp to the first container was then opened to allow the PC to flow from the first container, and the drip chamber was inverted and squeezed to fill the chamber. The drip chamber was then returned to its normal orientation, and the PC flowed through the drip chamber and leukocyte depletion assembly, toward the transfer container. Air was exhausted through the opened gas outlet, until the PC contacted the liquophobic membrane in the gas outlet.
At this point, flow stopped, the clamp on the conduit leading to the transfer container was opened, and PC flowed into the transfer container.
The conduits to the other five containers were then opened sequentially, and the PC flowed out of these containers. The PC passed through the drip chamber, where the air in the system elements leading to the five containers was collected, and then the PC passed through the leukocyte depletion assembly. The flow stopped when the six containers of PC had drained. At this point, PC remained in the leukocyte depletion assembly, the drip chamber, and the conduit downstream of the gas inlet. To recover some of this PC, the gas inlet was then uncapped, and the PC remaining in the drip chamber, conduits and half of the leukocyte depletion assembly drained into the storage container.
While the invention has been described in some detail by way of illustration and example, it should be understood that the invention is susceptible to various modifications and alternative forms, and is not restricted to the specific embodiments set forth. It should be understood that these specific embodiments are not intended to limit the invention but, on the contrary, the intention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the invention.

Claims

What is claimed is:
1. A system for processing biological fluid comprising: a pooling assembly; and at least one of a gas inlet and a gas outlet in fluid communication with the pooling assembly.
2. The system of claim 1 further comprising at least one of a drip chamber and a leukocyte depletion assembly in fluid communication with the pooling assembly.
3. The system of claim 1 further comprising a plurality of biological fluid source containers and a receiving container, wherein the pooling assembly is in fluid communication with the source containers and the receiving container.
4. The system of claim 3 further comprising interposed between the biological fluid source containers and the receiving container a gas inlet, a drip chamber, a leukocyte depletion assembly, and a gas outlet.
5. The system of claim 4 wherein at least one of a gas inlet, a drip chamber, a leukocyte depletion assembly, and a gas outlet is interposed between the pooling assembly and the receiving container.
6. A system for processing biological fluid comprising: a plurality of biological fluid source containers; a receiving container; a pooling assembly in fluid communication with the source containers and the receiving container; a leukocyte depletion assembly interposed between the pooling assembly and the receiving container; and at least one of a gas inlet and a gas outlet interposed between the source containers and the receiving container.
7. A system for processing biological fluid comprising: a pooling assembly; a plurality of biological fluid source containers in fluid communication with the pooling assembly; a receiving container in fluid communication with the pooling assembly; and interposed between the biological fluid source containers and the receiving container at least one of a gas inlet and a gas outlet.
8. The system of claim 7 further comprising at least one of a drip chamber and a leukocyte depletion assembly interposed between the source containers and the receiving container.
9. The system of claim 7 further comprising interposed between the biological fluid source containers and the receiving container a gas inlet, a drip chamber, a leukocyte depletion assembly, and a gas outlet.
10. The system of claim 9 wherein at least one of a gas inlet, a drip chamber, a leukocyte depletion assembly, and a gas outlet is interposed between the pooling assembly and the receiving container.
11. A system for processing biological fluid comprising: a pooling assembly having three or more inlets and an outlet; and a leukocyte depletion assembly in fluid communication with the pooling assembly.
12. A method for processing biological fluid comprising: introducing gas into a plurality of source containers of biological fluid; passing the biological fluid from the plurality of source containers through a pooling assembly to a receiving container; exhausting gas ahead of the biological fluid; and introducing gas behind the biological fluid to maximize recovery of the biological fluid.
13. The method of claim 12 further comprising introducing the gas into the plurality of source containers of biological fluid through at least one gas inlet in fluid communication with the plurality of source containers.
14. The method of claim 12 further comprising passing the biological fluid through at least one of a drip chamber and a leukocyte depletion assembly interposed between the pooling assembly and the receiving container.
15. A method for processing biological fluid comprising: introducing gas into a plurality of source containers of biological fluid; and passing biological fluid from the plurality of source containers through a pooling assembly and a leukocyte depletion assembly.
16. A method for processing biological fluid comprising: passing biological fluid through a pooling assembly and at least one leukocyte depletion assembly; and introducing gas behind the biological fluid to maximize recovery of the biological fluid.
17. A method for processing biological fluid comprising: passing a biological fluid through a pooling assembly to at least one device comprising at least one porous element for venting gas.
18. The method of claim 17 wherein passing the biological fluid to at least one device for separating gas from a biological fluid further comprises passing the biological fluid through a drip chamber.
19. The method of claim 17 wherein passing the biological fluid to at least one device for venting gas further comprises exhausting the gas through at least one gas outlet.
20. An apparatus for processing biological fluid comprising: a pooling assembly; and at least one device comprising at least one porous element in fluid communication with the pooling assembly, for venting gas.
21. The apparatus according to claim 20 wherein the device comprises at least one of a drip chamber, a gas inlet and a gas outlet.
22. The system of claim 3 wherein a gas inlet is in at least one of the source containers.
23. The system of claim 3 wherein the gas outlet is in the receiving container.
PCT/US1992/010034 1991-11-21 1992-11-20 System for processing separate containers of biological fluid WO1993009863A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
GB9409479A GB2276097B (en) 1991-11-21 1992-11-20 System for processing separate containers of biological fluid
JP50954293A JP3173009B2 (en) 1991-11-21 1992-11-20 System for processing individual containers of biological fluids
EP93900579A EP0675752B1 (en) 1991-11-21 1992-11-20 System and method for processing separate containers of biological fluid
DE69224219T DE69224219T2 (en) 1991-11-21 1992-11-20 SYSTEM AND METHOD FOR PROCESSING SEPARATE TANKS WITH BIOLOGICAL FLUIDUM

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79548091A 1991-11-21 1991-11-21
US07/795,480 1991-11-21

Publications (1)

Publication Number Publication Date
WO1993009863A1 true WO1993009863A1 (en) 1993-05-27

Family

ID=25165623

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1992/010034 WO1993009863A1 (en) 1991-11-21 1992-11-20 System for processing separate containers of biological fluid

Country Status (8)

Country Link
US (2) US5364526A (en)
EP (1) EP0675752B1 (en)
JP (1) JP3173009B2 (en)
AU (1) AU3220793A (en)
CA (1) CA2072378C (en)
DE (1) DE69224219T2 (en)
GB (1) GB2276097B (en)
WO (1) WO1993009863A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2692151A1 (en) * 1992-06-10 1993-12-17 Pall Corp Transition zone material processing system.
EP1064960A3 (en) * 1999-06-28 2002-01-02 Denco, Inc. Hemodialysis assembly and method
US6852231B2 (en) 2002-02-15 2005-02-08 Denco, Inc. Spin-hemodialysis assembly and method
WO2012062383A1 (en) * 2010-11-10 2012-05-18 Sartorius Weighing Technology Gmbh Container arrangement and method for filling flexible disposable bags

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5863436A (en) * 1990-05-24 1999-01-26 Pall Corporation Venting system
US5126054A (en) * 1990-05-24 1992-06-30 Pall Corporation Venting means
US5217627A (en) * 1990-11-06 1993-06-08 Pall Corporation System and method for processing biological fluid
GB9218581D0 (en) * 1992-09-02 1992-10-14 Pall Corp Removal of unwanted fluids from processed blood products
US5707520A (en) * 1993-06-27 1998-01-13 Terumo Kabushiki Kaisha Remover unit for use in filtration circuit for removing at least leukocyte
US6010633A (en) * 1997-03-06 2000-01-04 Hemasure Inc. Method of preventing air from becoming entrapped within a filtration device
US5472605A (en) * 1994-03-10 1995-12-05 Hemasure, Inc. Filtration device useable for removal of leukocytes and other blood components
US6251292B1 (en) 1994-03-10 2001-06-26 Hemasure, Inc. Method of preventing air from becoming entrapped within a filtration device
US5834660A (en) * 1995-04-10 1998-11-10 Alpha Therapeutic Corporation Method and system for testing blood samples
US5591573A (en) * 1995-04-10 1997-01-07 Alpha Therapeutic Corporation Method and system for testing blood samples
US5780222A (en) * 1995-04-10 1998-07-14 Alpha Therapeutic Corporation Method of PCR testing of pooled blood samples
CA2248931A1 (en) * 1996-05-01 1997-11-06 Pall Corporation Priming system
WO1998028057A1 (en) * 1996-12-24 1998-07-02 Pall Corporation Biological fluid processing
US6627532B1 (en) * 1998-02-11 2003-09-30 Applied Materials, Inc. Method of decreasing the K value in SiOC layer deposited by chemical vapor deposition
US6171493B1 (en) * 1998-03-20 2001-01-09 Lexion Medical Biological fluid filtration apparatus
US7651474B2 (en) 1999-10-01 2010-01-26 Caridianbct, Inc. Method and apparatus for leukoreduction of red blood cells
US6428712B1 (en) 2000-04-06 2002-08-06 Hemasure, Inc. Gravity driven liquid filtration system and method for filtering biological liquid
US7264608B2 (en) * 2001-12-05 2007-09-04 Fenwal, Inc. Manual processing systems and methods for providing blood components conditioned for pathogen inactivation
ATE522237T1 (en) * 2001-12-10 2011-09-15 Caridianbct Inc METHOD FOR REDUCING THE CONTENT OF LEUKOCYTES IN A RED BLOOD CELL COMPONENT
AU2002360840B2 (en) * 2001-12-31 2008-10-23 B. Braun Medical, Inc. Pharmaceutical compounding information management system
US7343224B2 (en) * 2001-12-31 2008-03-11 B. Braun Medical Inc. Pharmaceutical compounding systems and methods and information management system for same
US7317967B2 (en) * 2001-12-31 2008-01-08 B. Braun Medical Inc. Apparatus and method for transferring data to a pharmaceutical compounding system
US6994790B2 (en) * 2002-02-01 2006-02-07 Gambro, Inc. Whole blood collection and processing method
US20040127816A1 (en) * 2002-12-30 2004-07-01 Adriano Braun Galvao Handheld blood collection device
FR2856478B1 (en) * 2003-06-17 2006-05-19 Hemosystem METHOD AND DEVICE FOR COLLECTING AND MIXING LIQUID SAMPLES
US6951228B2 (en) * 2003-12-04 2005-10-04 B Braun Medical Inc. Bulk compounder manifold
US20050137517A1 (en) * 2003-12-19 2005-06-23 Baxter International Inc. Processing systems and methods for providing leukocyte-reduced blood components conditioned for pathogen inactivation
US7204277B2 (en) * 2004-09-16 2007-04-17 B. Braun Medical Inc. By-pass line connector for compounding system
DE102010030371A1 (en) * 2010-06-22 2013-08-22 Terumo Bct, Inc. Connection method and workstation suitable for carrying out the method
US9744498B2 (en) 2011-03-11 2017-08-29 Fenwal, Inc. Disposable fluid circuits and methods for cell washing with on-line dilution of cell feed
EP2720730B1 (en) * 2011-09-22 2017-01-11 Fenwal, Inc. Disposable fluid circuits and methods for cell washing
US9782707B2 (en) 2014-03-24 2017-10-10 Fenwal, Inc. Biological fluid filters having flexible walls and methods for making such filters
US9796166B2 (en) 2014-03-24 2017-10-24 Fenwal, Inc. Flexible biological fluid filters
US10376627B2 (en) 2014-03-24 2019-08-13 Fenwal, Inc. Flexible biological fluid filters
US9968738B2 (en) 2014-03-24 2018-05-15 Fenwal, Inc. Biological fluid filters with molded frame and methods for making such filters
US10159778B2 (en) 2014-03-24 2018-12-25 Fenwal, Inc. Biological fluid filters having flexible walls and methods for making such filters
KR101708900B1 (en) 2014-11-04 2017-02-21 엘이디라이팅 주식회사 Led flood light
US10596532B2 (en) * 2016-11-16 2020-03-24 Zyno Medical, Llc Isolatable automatic drug compounding system
CA2987101A1 (en) * 2016-12-01 2018-06-01 Fenwal, Inc. Blood component pooling device, system and method
WO2019059235A1 (en) * 2017-09-19 2019-03-28 株式会社メガカリオン Method for manufacturing purified blood platelets, method for manufacturing blood platelet preparation, method for manufacturing blood preparation, blood platelet preservation fluid, blood platelet preservation agent, and method for preserving blood platelets

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4360435A (en) * 1979-11-01 1982-11-23 Baxter Travenol Laboratories, Inc. Process for sterilizing and transferring a solution
US4701267A (en) * 1984-03-15 1987-10-20 Asahi Medical Co., Ltd. Method for removing leukocytes
US4985153A (en) * 1988-06-23 1991-01-15 Asahi Medical Co., Ltd. Method for separating blood into blood components, and blood components separator unit
US5056568A (en) * 1986-12-05 1991-10-15 Clintec Nutrition Company Automated system for adding multiple fluids to a single container
US5074839A (en) * 1989-08-24 1991-12-24 Hemotrans, Inc. Blood transfer apparatus
US5126054A (en) * 1990-05-24 1992-06-30 Pall Corporation Venting means

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2781064A (en) * 1954-05-28 1957-02-12 Gould National Batteries Inc Electrolyte dispensing apparatus
US3000540A (en) * 1957-08-08 1961-09-19 Baxter Laboratories Inc Flow control device and method
US3631654A (en) * 1968-10-03 1972-01-04 Pall Corp Gas purge device
US3650093A (en) * 1970-01-08 1972-03-21 Pall Corp Sterile disposable medicament administration system
US3941126A (en) * 1974-08-08 1976-03-02 Dietrich Joseph W Apparatus for long term intravenous administration of diluted incompatible multiple medications
US4126558A (en) * 1975-01-31 1978-11-21 Johnson & Johnson Blood filtration unit with manual vent means
JPS5359017A (en) * 1976-11-02 1978-05-27 Terumo Corp Fractionation and purification of red blood corpuscle
US4191183A (en) * 1977-10-31 1980-03-04 Barry Mendelson Mixing chamber for use in plural medical liquid intravenous administration set
US4276170A (en) * 1978-08-16 1981-06-30 Critikon, Inc. Vented flexible filtration device for use in administering parenteral liquids
FR2468400A1 (en) * 1979-11-01 1981-05-08 Baxter Travenol Lab METHOD AND DEVICE FOR MIXING HYPERNUTRIENT SOLUTIONS
US4334535A (en) * 1980-08-12 1982-06-15 Cutter Laboratories, Inc. Conduit device for rapid priming and flow of liquid
US4459139A (en) * 1981-09-14 1984-07-10 Gelman Sciences Inc. Disposable filter device and liquid aspirating system incorporating same
US4507119A (en) * 1982-07-06 1985-03-26 E. I. Du Pont De Nemours And Company Sterile docking process, apparatus and system
US4680025A (en) * 1982-08-24 1987-07-14 Baxter Travenol Laboratories, Inc. Blood component collection systems and methods
US4857190A (en) * 1984-03-02 1989-08-15 Miles Laboratories, Inc. Container for fine separation of blood and blood components
DE3602075C1 (en) * 1986-01-24 1987-07-23 Fresenius Ag Method and device for producing mixtures of pharmaceutical liquids
US4900322A (en) * 1986-09-22 1990-02-13 Adams James D Blood component pooling valve and kit
US5098371A (en) * 1987-10-24 1992-03-24 Kawasumi Laboratories, Inc. Switch bag type blood gathering set
JPH0614969B2 (en) * 1988-03-15 1994-03-02 テルモ株式会社 Liquid filtration device
DE8903605U1 (en) * 1989-03-22 1989-06-29 Fresenius Ag, 6380 Bad Homburg, De
US5100564A (en) * 1990-11-06 1992-03-31 Pall Corporation Blood collection and processing system
US5102407A (en) * 1990-03-13 1992-04-07 Miles Inc. Blood separation system
JP2838725B2 (en) * 1990-05-02 1998-12-16 テルモ株式会社 Blood collection equipment
US5217627A (en) * 1990-11-06 1993-06-08 Pall Corporation System and method for processing biological fluid

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4360435A (en) * 1979-11-01 1982-11-23 Baxter Travenol Laboratories, Inc. Process for sterilizing and transferring a solution
US4701267A (en) * 1984-03-15 1987-10-20 Asahi Medical Co., Ltd. Method for removing leukocytes
US4701267B1 (en) * 1984-03-15 1996-03-12 Asahi Medical Co Method for removing leukocytes
US5056568A (en) * 1986-12-05 1991-10-15 Clintec Nutrition Company Automated system for adding multiple fluids to a single container
US4985153A (en) * 1988-06-23 1991-01-15 Asahi Medical Co., Ltd. Method for separating blood into blood components, and blood components separator unit
US5074839A (en) * 1989-08-24 1991-12-24 Hemotrans, Inc. Blood transfer apparatus
US5126054A (en) * 1990-05-24 1992-06-30 Pall Corporation Venting means

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2692151A1 (en) * 1992-06-10 1993-12-17 Pall Corp Transition zone material processing system.
BE1006569A5 (en) * 1992-06-10 1994-10-18 Pall Corp Material processing system of transition zone.
US5670060A (en) * 1992-06-10 1997-09-23 Pall Corporation Method for treating a biological fluid including transition zone material
EP1064960A3 (en) * 1999-06-28 2002-01-02 Denco, Inc. Hemodialysis assembly and method
US6852231B2 (en) 2002-02-15 2005-02-08 Denco, Inc. Spin-hemodialysis assembly and method
WO2012062383A1 (en) * 2010-11-10 2012-05-18 Sartorius Weighing Technology Gmbh Container arrangement and method for filling flexible disposable bags
US9365304B2 (en) 2010-11-10 2016-06-14 Sartorius Lab Instruments Gmbh & Co. Kg Container arrangement and method for filling flexible disposable bags

Also Published As

Publication number Publication date
GB2276097A (en) 1994-09-21
CA2072378C (en) 2000-12-26
DE69224219D1 (en) 1998-02-26
US5364526A (en) 1994-11-15
AU3220793A (en) 1993-06-15
DE69224219T2 (en) 1998-08-13
EP0675752B1 (en) 1998-01-21
CA2072378A1 (en) 1993-05-22
EP0675752A4 (en) 1994-10-24
EP0675752A1 (en) 1995-10-11
US5470488A (en) 1995-11-28
GB9409479D0 (en) 1994-07-27
JP3173009B2 (en) 2001-06-04
GB2276097B (en) 1995-10-18
JPH07501033A (en) 1995-02-02

Similar Documents

Publication Publication Date Title
EP0675752B1 (en) System and method for processing separate containers of biological fluid
US5545339A (en) Method for processing biological fluid and treating separated component
US5472621A (en) Method for treating transition zone material
JP3885770B2 (en) Ventilation system
CA2137797C (en) System for treating transition zone material
EP0540732B1 (en) Systems and methods for removing undesired matter from blood cells
US6059968A (en) Systems for processing and storing placenta/umbilical cord blood
AU2006320987B2 (en) Prechargeable fluid filtration method and apparatus
AU736156B2 (en) Biological fluid processing
WO2000007642A1 (en) Biological fluid processing system
US20120181236A1 (en) Prechargable fluid filtration method and apparatus

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AT AU BB BG BR CA CH CS DE DK ES FI GB HU JP KP KR LK LU MG MN MW NL NO PL RO RU SD SE

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL SE BF BJ CF CG CI CM GA GN ML MR SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 9409479.4

Country of ref document: GB

WWE Wipo information: entry into national phase

Ref document number: 1993900579

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

WWP Wipo information: published in national office

Ref document number: 1993900579

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1993900579

Country of ref document: EP